EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expanding the Knowledge of the Molecular Effects and Therapeutic Potential of Incomptine A for the Treatment of Non-Hodgkin Lymphoma: In Vivo and Bioinformatics Studies, Part III

Normand García-Hernández iD, Fernando Calzada iD, Elihú Bautista iD, José Manuel Sánchez-López iD, Miguel Valdes iD, Claudia Velázquez iD, Elizabeth Barbosa iD

Pharmaceuticals · 25.08.2025 · 18 (9) · 1263

DOI: 10.3390/ph18091263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 25.08.2025. Verfasst von Normand García-Hernández und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Investigación Médica en Genética Humana, UMAE Hospital Pediatría 2° Piso, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro S…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Mexicano del Seguro Social.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Non-Hodgkin lymphoma (NHL) is a group of blood cancers that arise in the lymphatic nodes and other tissues after an injury to the DNA of B/T lineage and NK lymphocytes. Recently, we reported that incomptine A (IA) has in vivo antilymphoma properties. This research aimed to evaluate the effects of IA in the treatment of NHL using antilymphoma activity, Tandem Mass Tag (TMT), and bioinformatics approaches.

Methods

The antilymphoma activity of IA was tested on male Balb/c mice inoculated with U-937 cells. Also, TMT, gene ontology enrichment, Reactome pathway, Kyoto Encyclopedia of Gene and Genomes pathway, molecular docking, toxicoinformatic, and pharmaceutical analyses were performed.

Results

By TMT analysis of the altered levels of proteins present in the lymph nodes of Balb/c mice with NHL and treated with IA, we identified 106 significantly differentially expressed proteins (DEPs), including Il1rap, Ifi44, Timd4, Apoa4, and Fabp3 as well as Myh3, Eno 2, and H4c11. Among these, the Fhl1 result was the most important cluster altered and a potential core target of IA for the treatment of NHL. Network pharmacology studies have revealed that DEPs are associated with processes such as muscle contraction, glycolysis, hemostasis, epigenetic regulation of gene expression, transport of small molecules, neutrophil extracellular trap formation, adrenergic signaling in cardiomyocytes, systemic lupus erythematosus, alcoholism, and platelet activation, signaling, and aggregation. Computational studies revealed strong binding affinities with six proteins associated with cancer, positive pharmacokinetic properties, and no toxicity.

Conclusions

Our contribution suggests that IA may be a compound with potential therapeutic effects against NHL.

Schlagwörter

Stichwörter der Autor:innen

Tandem Mass Tagantilymphoma activityincomptine Amolecular dockingnetwork pharmacologynon-Hodkin lymphomapharmaceutical analysistoxicoinformatic

Autor:innen und Institutionen

  • Unidad de Investigación Médica en Genética Humana, UMAE Hospital Pediatría 2° Piso, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Av. Cuauhtémoc 330, Col. Doctores, Mexico City 06725, Mexico.
  • Unidad de Investigación Médica en Farmacología, UMAE Hospital de Especialidades, 2° Piso CORSE, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Av. Cuauhtémoc 330, Col. Doctores, Mexico City 0672…
  • CONAHCYT-División de Biología Molecular, Instituto Potosino de Investigación Científica y Tecnológica A. C, San Luis Potosí 78216, Mexico.
  • Hospital Infantil de Tlaxcala, Investigación y Enseñanza, 20 de Noviembre S/M, San Matias Tepetomatitlan, Apetatitlan de de Antonio Carvajal, Tlaxcala 90606, Mexico.
  • Phagocytes Architecture and Dynamics, IPBS, UMR5089 CNRS-Université Toulouse 3, 205 Route de Narbonne, 31077 Toulouse, France.
  • Instituto Politécnico Nacional, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Plan de San Luis y Salvador Díaz Mirón S/N, Col. Casco de Santo Tomás, Miguel Hidalgo, Mexico City 11340, Me…

ORCID-Profile: Normand García-Hernández, Fernando Calzada, Elihú Bautista, José Manuel Sánchez-López, Miguel Valdes, Claudia Velázquez, Elizabeth Barbosa

Förderung

  • Instituto Mexicano del Seguro Social

Zitieren

APA

García-Hernández, N., Calzada, F., Bautista, E., Sánchez-López, J. M., Valdes, M., Velázquez, C., & Barbosa, E. (2025). Expanding the Knowledge of the Molecular Effects and Therapeutic Potential of Incomptine A for the Treatment of Non-Hodgkin Lymphoma: In Vivo and Bioinformatics Studies, Part III. Pharmaceuticals, 18(9), 1263. https://doi.org/10.3390/ph18091263

Vancouver

García-Hernández N, Calzada F, Bautista E, Sánchez-López JM, Valdes M, Velázquez C, et al. Expanding the Knowledge of the Molecular Effects and Therapeutic Potential of Incomptine A for the Treatment of Non-Hodgkin Lymphoma: In Vivo and Bioinformatics Studies, Part III. Pharmaceuticals. 2025;18(9):1263. doi:10.3390/ph18091263

BibTeX
@article{GarcaHernndez2025,
  author = {García-Hernández, Normand and Calzada, Fernando and Bautista, Elihú and Sánchez-López, José Manuel and Valdes, Miguel and Velázquez, Claudia and Barbosa, Elizabeth},
  title = {Expanding the Knowledge of the Molecular Effects and Therapeutic Potential of Incomptine A for the Treatment of Non-Hodgkin Lymphoma: In Vivo and Bioinformatics Studies, Part III},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {9},
  pages = {1263},
  doi = {10.3390/ph18091263}
}
Kostenlos starten →